Yoshikazu Yonemitsu

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.

GAIA BioMedicine Inc. engages in the development of regenerative medicine and other product development. Its products include medicines for cell and gene therapy. It also offers services on drug screening and advance medical support. The company was founded by Yoshikazu Yonemitsu in October 2015 and is headquartered in Fukuoka, Japan.